This mechanism of action differs from other therapies in MS with effects on PDCs, such as IFN-β treatment, which has been shown to directly affect PDCs during in vitro stimulation resulting in reduced proinflammatory cytokine secretion, reduced expression of CCR7, increased expression of programmed death ligand 1 (PD-L1), and increased IL-10 secretion [32]. Here, IL10 is linked to myeloid sarcoma.